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Long believed to be a byproduct of malignant trans-
formation, reprogramming of cellular metabolism
is now recognized as a driving force in tumorigenesis.
In clear cell renal cell carcinoma (ccRCC), frequent
activation of HIF signaling induces a metabolic
switch that promotes tumorigenesis. Here, we
demonstrate that PGC-1a, a central regulator of en-
ergy metabolism, is suppressed in VHL-deficient
ccRCC by a HIF/Dec1-dependent mechanism. In
VHL wild-type cells, PGC-1a suppression leads to
decreased expression of the mitochondrial tran-
scription factor Tfam and impaired mitochondrial
respiration. Conversely, PGC-1a expression in VHL-
deficient cells restores mitochondrial function and
induces oxidative stress. ccRCC cells expressing
PGC-1aexhibit impaired tumorgrowthandenhanced
sensitivity to cytotoxic therapies. In patients, low
levels of PGC-1a expression are associated with
poor outcome. These studies demonstrate that sup-
pression of PGC-1a recapitulates key metabolic
phenotypes of ccRCC and highlight the potential of
targetingPGC-1a expression as a therapeuticmodal-
ity for the treatment of ccRCC.
INTRODUCTION
First observed by Otto Warburg in the early 20th century, meta-
bolic reprogramming is now accepted as an emerging hallmark
of cancer (Hanahan andWeinberg, 2011). Constitutive activation
of hypoxia inducible factor (HIF) signaling and accumulation of
cytosolic lipid droplets indicate profound changes in cellular
metabolism take place during clear cell renal cell carcinoma
(ccRCC) tumorigenesis. Indeed, the signaling networks that
regulate metabolic behavior are frequently altered in ccRCC,
leading to the description of this tumor type as a ‘‘metabolic dis-
ease’’ (Linehan et al., 2010). Despite the seemingly important role116 Cell Reports 12, 116–127, July 7, 2015 ª2015 The Authorsof altered metabolism in ccRCC tumorigenesis, the molecular
mechanisms underlying these metabolic shifts are incompletely
understood. Clinically, ccRCC is refractory to conventional cyto-
toxic agents, with therapeutic approaches instead favoring sur-
gery and targeted therapies such as tyrosine kinase inhibitors,
mTOR inhibitors, and immunotherapy (Rini et al., 2009). Impor-
tantly, the mechanism of resistance to chemo/radiotherapy is
poorly understood, and whether altered metabolism influences
therapeutic response remains unknown.
Deletions and mutations to the tumor suppressor gene Von
Hippel-Lindau (Vhl) are the most frequent genetic alterations in
ccRCC (Cancer Genome Atlas Research Network, 2013; Gnarra
et al., 1994). The Vhl gene encodes an E3 ubiquitin ligase that is
essential for oxygen-dependent regulation of HIF-a transcription
factors (Kondo et al., 2002; Maxwell et al., 1999). In normal oxy-
gen conditions, HIF-1a and HIF-2a subunits are hydroxylated on
key proline residues by oxygen-dependent prolyl hydroxylases
(PHDs), bound by VHL, and rapidly degraded by the proteasome
(Ivan et al., 2001; Jaakkola et al., 2001). In hypoxia, prolyl hydrox-
ylation is inhibited, resulting in HIF-a stabilization and dimeriza-
tion with aryl hydrocarbon receptor nuclear transactivator
(ARNT) (Wang et al., 1995). Consequently, VHL loss of function
results in constitutive activation of HIF-a, which promotes tumor-
igenesis through transcriptional activation of genes involved in
angiogenesis, invasion, metastasis, and metabolism (Gordan
and Simon, 2007).
Constitutive activation of HIF transcription factors is thought
to be a primary driving force of metabolic reprogramming in
ccRCC. HIF transcription factors activate a gene expression pro-
gram that upregulates glycolytic flux while simultaneously inhib-
iting mitochondrial activity (Fukuda et al., 2007; Papandreou
et al., 2006). The ability of HIF to negatively regulate mitochon-
drial activity fits with the evolutionary need for coupling oxygen
consumption in the mitochondria to nutrient and oxygen avail-
ability. In ccRCC, mitochondrial content is inversely correlated
with tumor grade, indicating that suppression of mitochondrial
activity may play an important role in ccRCC progression (Si-
monnet et al., 2002). Importantly, the mechanism underlying
suppression of mitochondrial content in ccRCC, and the conse-
quences thereof, remain incompletely understood.
The PPARg coactivators (PGC) are a family of transcriptional
coactivators that are regulated by a wide range of environmental
stimuli to coordinate mitochondrial biogenesis and metabolic
flux (Puigserver et al., 1998). While the PGC coactivators (con-
sisting of PGC-1a, PGC-1b, and PRC) exhibit some degree of
redundancy, PGC-1a-knockout mice exhibit multi-tissue de-
fects in mitochondrial metabolism indicating unique functions
for PGC-1a that cannot be compensated for by the other family
members (Leone et al., 2005; Lin et al., 2004). Although a
growing body of evidence points toward an important role for
PGC-1a in cancer, an important dichotomy exists, with reports
of pro and anti-tumorigenic effects of PGC-1a expression in
different cancer types (D’Errico et al., 2011; Haq et al., 2013;
LeBleu et al., 2014; Lim et al., 2014; Vazquez et al., 2013; Yan
et al., 2014). A better understanding of the role of PGC-1a in
different tumor types and at different stages of tumorigenesis
will be important in determining whether this pathway will be
amenable to therapeutic intervention.
Past studies indicate that dynamic interplay between the HIF
transcription factors and c-Myc can regulate expression of
PGC-1b andmitochondrial biogenesis (Zhang et al., 2007). Addi-
tionally, hypoxia has been linked to the regulation of PGC-1a
in adipose tissue, where hypoxia inhibits SIRT2-mediated de-
acetylation of PGC-1a (Krishnan et al., 2012). Conversely,
PGC-1a-induced oxygen consumption and reactive oxygen
species (ROS) production have been reported to stabilize and
activate HIFs (O’Hagan et al., 2009; Shoag and Arany, 2010).
To this point, it has remained unclear whether PGC-1a expres-
sion or activity is modulated in ccRCC and, if so, what effect
this regulation would have on the metabolic phenotypes and
tumorigenic potential of ccRCC.
RESULTS
Suppression of Mitochondrial Biogenesis Transcription
Factors in ccRCC
To explore the gene expression changes underlying metabolic
alteration in ccRCC, we analyzed previously published microar-
ray datasets from ccRCC cell lines and tumors. Gene set enrich-
ment analysis (GSEA) revealed significant enrichment of hypoxia
gene sets and depletion of b-oxidation and tricarboxylic acid
(TCA) cycle gene sets in ccRCC compared to the non-malignant
kidney (Figures 1A, S1A, and S1B). Furthermore, Database for
Annotation, Visualization, and Integrated Discovery (DAVID)
analysis revealed suppression of genes involved inmitochondrial
function in VHL-deficient ccRCC cells in vitro (Figures 1B and
S1C). We hypothesized that these changes in gene expression
might result from suppression of the key transcriptional regula-
tors of mitochondrial biogenesis.
Mitochondrial biogenesis is controlled by a network of nuclear
transcription factorsandcoactivators that include thenuclear res-
piratory factors (NRFs), the estrogen-related receptors (ERRs),
and the PGC family of transcriptional coactivators. To determine
whether differential expression of these transcriptional regulators
could explain the gene expression changes outlined above,
we profiled the expression of several genes known to act as
regulators of these pathways. To our surprise, PGC-1a, but not
PGC-1b, was highly suppressed in ccRCC (Figures 1C, S2A,and S2B). Additionally, expression of the mitochondrial tran-
scription factor Tfam (a known target of PGC-1a) was decreased
in ccRCC, as was ERRa, a transcription factor through which
PGC-1a function is transduced (Mootha et al., 2004) (Figure 1C).
Consistent with these data, PGC-1a mRNA and protein were
suppressed in several VHL-deficient cell lines (Figures 1D–1F
and S2C). Given its central role as a regulator of mitochondrial
function, we hypothesized that suppression of PGC-1a disrupts
mitochondrial content and function in ccRCC.
PGC-1a Is Essential for Mitochondrial Homeostasis in
Renal Proximal Tubule Cells
Studies using genetically engineeredmousemodels indicate that
PGC-1adeficiency results in defectivemitochondrialmetabolism
in multiple tissue types (Leone et al., 2005). Similarly, VHL-defi-
cient ccRCC cell lines exhibit HIF-dependent decreases in mito-
chondrial content and activity (Figures S3A–S3D). We reasoned
that the suppression of PGC-1a in VHL-deficient ccRCC could
underlie themitochondrial deficiency characteristic of this cancer
type. Consistent with this hypothesis, PGC-1a knockdown in
VHL wild-type malignant (TK10) and non-malignant proximal
tubule (HK2) cells decreased expression of the essential mito-
chondrial transcription factor Tfam (Figure 2A). Importantly,
PGC-1a suppression also functionally impaired mitochondrial
oxygen consumption rates (OCR) in both HK2 and TK10 cells,
indicating that endogenous expression of PGC-1a is essential
formaintaining basal mitochondrial respiration in these cells (Fig-
ures 2B and S3E–S3G). Consistent with impaired mitochondrial
function in PGC-1a-deficient cells, gas chromatography-mass
spectrometry (GC-MS) analysis revealed significant decreases
in TCA cycle metabolite abundance (Figure 2C). These results
indicate that PGC-1a expression is essential for mitochondrial
function and suggest that suppression of PGC-1amaycontribute
to the depletion of mitochondrial function observed in ccRCC.
To further explore the role of PGC-1a suppression in ccRCC
metabolism, we tested whether restored PGC-1a expression in
VHL-deficient cells was sufficient to rescue mitochondrial func-
tion (Figure 2D). Consistent with increased mitochondrial con-
tent, PGC-1a expression in VHL-deficient RCC4 and 786-O
cells increased mtDNA content and CMXRos staining (Figures
2E and S3H). PGC-1a expression also functionally increased
mitochondrial respiration in both RCC4 and 786-O cells, an
effect that was significantly blunted by withdrawal of exoge-
nous glutamine (Figure 2F). Increased mitochondrial respiration
was also partially sensitive to the CPT-1a inhibitor etomoxir,
indicating that PGC-1a stimulation of OCR occurred at least
in part due to increases in b-oxidation (Figures S3I and S3J).
These results provide evidence that restored PGC-1a expres-
sion is sufficient to restore mitochondrial content and function
in VHL-deficient ccRCC.
PGC-1a function is transduced through interaction with a wide
range of nuclear transcription factors, and we next sought to
identify the transcription factor(s) acting in concert with PGC-
1a to stimulate mitochondrial biogenesis in ccRCC. Using small
interfering RNA (siRNA) to transiently suppress expression of
several transcription factors known to interact with PGC-1a,
we determined that ERRa was required for PGC-1a-induced
mitochondrial gene expression in VHL-deficient RCC4 cellsCell Reports 12, 116–127, July 7, 2015 ª2015 The Authors 117
Figure 1. PGC-1a Expression Is Suppressed in VHL-Deficient Clear Cell Renal Cell Carcinoma
(A) GSEA of normal kidney and ccRCC tumors. *Zero cross at 7,239 (GEO:GSE6344).
(B) DAVID analysis of gene expression in RCC4 cells in VHL deficiency or hypoxia. (Array data from Krieg et al., 2010).
(C) mRNA expression levels in normal kidney or ccRCC. Data fromGEO:GSE6344. *p < 0.04; **p < 0.03; ***p < 0.0001; n.s., p > 0.05 by Student’s two-tailed t test.
(D) mRNA levels in VHL-deficient (VHL) or wild-type (+VHL) RCC4 cells. *p < 0.0001 by Student’s two-tailed t test.
(E) mRNA levels in VHL-deficient (VHL) or wild-type (+VHL) RCC4 and 786-O cells. *p = 0.01; **p = 0.001 by Student’s two-tailed t test.
(F) PGC-1a protein levels in VHL-deficient (VHL) or wild-type (+VHL) RCC4 and 786-O cells.
All bar graphs are plotted as mean ± SD. See also Figures S1 and S2.(Figures 2G and S3K). Furthermore, ERRa suppression also
abrogated the PGC-1a-increased mitochondrial respiration
rate, indicating its essential role as a co-regulator of PGC-1a in
regulating mitochondrial function (Figure 2H). These results indi-
cate that ERRa is required for PGC-1a-mediated induction of
mitochondrial biogenesis in ccRCC.
PGC-1a Induces Oxidative Stress and Sensitizes ccRCC
Cells to Cytotoxic Therapy
ROS are potent byproducts of electron transport chain activity
and play a complex role in tumorigenesis. Malignant cells often
exhibit elevated steady-state levels of ROS, rendering them118 Cell Reports 12, 116–127, July 7, 2015 ª2015 The Authorsexquisitely sensitive to further increases in ROS production
from the mitochondria (Trachootham et al., 2009). We reasoned
that the elevated mitochondrial respiratory activity observed
upon expression of PGC-1a would likely be accompanied by
an increase in ROS production. Furthermore, VHL-deficient
ccRCC cell lines exhibit HIF-dependent decreases in both mito-
chondrial respiration and ROS production, indicating that the
two processes are functionally linked (Figures S3C and S4A).
In support of this hypothesis, RCC4 and 786-O cells ectopically
expressing PGC-1a contained significantly elevated levels of
hydroxyl and superoxide radicals as measured by DCF-DA and
MitoSOX staining, respectively (Figures 3A, 3B, and S4B). These
Figure 2. PGC-1a Regulates Mitochondrial Homeostasis and OXPHOS Activity in ccRCC
(A) Western blots of VHL wild-type HK2 and TK10 cells transduced with shCTRL or shPGC-1a.
(B) Oxygen consumption rates (OCRs) in HK2 and TK10 cells transduced with shCTRL or shPGC-1a. Oligomycin (Oligo), FCCP, and antimycin A/rotenone
(Anti/Rot) were injected at the indicated time points. Data presented asmean + SEM. Student’s two-tailed t test calculated by pooling the threemeasurements for
each condition **p% 0.01; *p < 0.05.
(C) GC-MS quantification of TCA cycle metabolites from shCTRL and shPGC-1a-transduced HK2 cells *p% 0.01 by Student’s two-tailed t test.
(D) Ectopic expression of PGC-1a in VHL-deficient RCC4 and 786-O cells.
(E) mtDNAmeasurements normalized to nuclear DNA (nDNA) in CTRL or PGC-1a transduced RCC4 and 786-O cells. *p = 0.01; **p < 0.03 by Student’s two-tailed
t test.
(F) OCR measurements in CTRL and PGC-1a-transduced RCC4 and 786-O cells cultured with the indicated carbon sources. *,#Two-tailed Student’s t test
p < 0.0001.
(G) qPCR analysis of mitochondrial gene expression in RCC4 cells transduced with control (C) or PGC-1a retrovirus and transfected with the indicated siRNA.
*Two-tailed Student’s t test p < 0.05.
(H) Basal OCR in CTRL and PGC-1a transduced RCC4 cells transfected with the indicated siRNA. *, #Two-tailed Student’s t test p < 0.0001.
All bar graphs are plotted as mean ± SD unless otherwise noted. See also Figure S3.results were surprising given the known ability of PGC-1a to
coordinate expression of ROS detoxification enzymes with
enhanced mitochondrial biogenesis (St-Pierre et al., 2006).
Indeed, PGC-1a expression in VHL-deficient cells did increase
the expression of several antioxidant genes (Figure 3C). To
determine whether the antioxidant response was sufficient to
detoxify the observed increases in ROS, we next stained for
8-hydroxyguanosine (8oxoG), an oxidized derivative of guano-
sine that is commonly used as a biomarker of oxidative stress.
Strikingly, both RCC4 and 786-O cells transduced with PGC-
1a exhibited significantly elevated levels of 8oxoG compared
to control, indicating that PGC-1a expression was sufficient to
induce oxidative stress in VHL-deficient ccRCC cells (Figures
3D and S4C). Furthermore, PGC-1a expression increased
gH2AX levels in RCC4 cells, indicating the presence of an activeDNA damage response (Figure 3E). These results suggest
that PGC-1a-induced mitochondrial activity is tightly associated
with oxidative stress in VHL-deficient cells.
ccRCC is resistant to cytotoxic chemotherapy and radio-
therapy, and we hypothesized that PGC-1a would sensitize
ccRCC cells to cytotoxic therapies. To test this hypothesis, we
exposed RCC4 cells to doxorubicin and found that ectopic
expression of PGC-1a sensitized ccRCC cells to doxorubicin
treatment (Figures 3F). Consistent with this result, RCC4 cells
transduced with PGC-1a exhibited a significant decrease in
clonogenic survival compared to control (Figure 3G). Similarly,
PGC-1a expression dramatically sensitized RCC4 cells to
ionizing radiation as measured using the clonogenic survival
assay (Figure 3H). These results indicate that therapeutic induc-
tion of PGC-1a expression may be an unrecognized mechanismCell Reports 12, 116–127, July 7, 2015 ª2015 The Authors 119
Figure 3. PGC-1a Increases Oxidative Stress in ccRCC and Enhances Sensitivity to Cytotoxic Therapies
(A) Mean DCF-DA staining of control (CTRL) or PGC-1a-transduced RCC4 cells. *p < 0.001 by Student’s two-tailed t test.
(B) Mean MitoSOX staining intensity in control or PGC-1a-transduced RCC4 cells. *p < 0.0002 by Student’s two-tailed t test.
(C) mRNA levels of the indicated genes in CTRL and PGC-1a-transduced RCC4 cells. *p < 0.025; n.s., p > 0.05 by Student’s two-tailed t test.
(D) 8-hydroxyguanosine (8oxoG) immunofluorescent (IF) staining of CTRL and PGC-1a-transduced RCC4 cells treated with vehicle (Veh) or 0.1 mg/ml doxorubicin
(Dox) for 48 hr. Scale bar, 100 mm.
(E) Phosphorylated histone H2A.x (Ser 139) (gH2AX) IF staining of CTRL and PGC-1a-transduced RCC4 cells treated with Veh or Dox for 48 hr. Scale bar, 100 mm.
(F) XTT assay of CTRL and PGC-1a-transduced RCC4 cells treated with the indicated dose of doxorubicin for 48 hr. Half maximal inhibitory concentration
for doxorubicin killing indicated by a dashed line (CTRL = 0.23 mM, PGC-1a = 0.04 mM).
(G) Clonogenic survival of CTRL and PGC-1a-transduced RCC4 cells treated with the indicated concentration of doxorubicin. *p < 0.02; **p = 0.01 by Student’s
two-tailed t test.
(H) Clonogenic survival of CTRL and PGC-1a-transduced RCC4 cells treated with 0, 2, 4, or 6 Gy ionizing radiation.
All bar graphs are plotted as mean ± SD. See also Figure S4.to enhance the efficacy of chemotherapy and radiotherapy in the
treatment of ccRCC.
HIF-a-Dependent Suppression of PGC-1a in VHL
Deficiency and Hypoxia
To further assess the potential of PGC-1a induction as a thera-
peutic modality in ccRCC, we sought to characterize the molec-
ular mechanisms underlying suppression of PGC-1a in ccRCC.
The tumor suppressor function of VHL is tightly linked with its120 Cell Reports 12, 116–127, July 7, 2015 ª2015 The Authorsability to regulate the stability of HIF-1a and HIF-2a. To deter-
mine whether PGC-1a suppression in VHL-deficient ccRCC
cells required HIF-a expression, we used small hairpin RNAs
(shRNAs) to target expression of either HIF-1a or HIF-2a. Indi-
cating an essential role for HIFs in mediating PGC-1a suppres-
sion, knockdown of either HIF-1a or HIF-2a resulted in increased
PGC-1a expression in VHL-deficient RCC4 and 786-O cells, indi-
cating that HIF-a expression is required for suppression of PGC-
1a (Figures 4A, 4B, and S5A). We further probed the role of HIF
transcriptional regulatory activity in PGC-1a suppression by as-
sessing whether the obligate HIF-a binding partner, ARNT, was
required for PGC-1a suppression. Consistent with the results
from HIF-1a and HIF-2a knockdown, suppression of ARNT re-
sulted in increased levels of PGC-1a protein and mRNA in VHL-
deficient cells (Figures 4C, 4D, and S5B). These results demon-
strate that a functional HIF-a/ARNT transcriptional complex is
required for suppression of PGC-1a in VHL-deficient ccRCC.
Although prevalent in ccRCC, VHL loss-of-function mutations
are rare in most tumor types. In contrast, hypoxia is a nearly
ubiquitous characteristic of solid tumors. To determine whether
HIF-dependent regulation of PGC-1a is intact in VHL wild-type
cells exposed to low oxygen tensions, we compared expression
of PGC-1a protein andmRNA in cell lines cultured in normoxia or
hypoxia. Consistent with our results in VHL-deficient cells,
hypoxia suppressed PGC-1a protein and mRNA levels in both
non-transformed HK2 proximal tubule cells and in VHL wild-
type TK10 ccRCC cells (Figures 4E and 4F). When compared
to normoxia counterparts, knockdown of HIF-1a blunted the
decrease in PGC-1a mRNA and protein in cells exposed to
hypoxia, indicating that this effect was HIF dependent (Figures
4G, 4H, and S5C). Similarly, HIF-a stabilization induced by
treatment with the prolyl hydroxylase inhibitor dimethyloxaloyl-
glycine (DMOG) resulted in HIF-1a-dependent suppression of
PGC-1a mRNA (Figure 4I). Treatment with DMOG also resulted
in HIF-1a-dependent inhibition of Ppargc1a promoter activity,
indicating that diminished expression of PGC-1a likely occurs
at least in part through transcriptional repression (Figure 4J).
These results demonstrate that PGC-1a transcription is inhibited
in a HIF-dependent manner in ccRCC.
Dec1 Is Necessary and Sufficient for Transcriptional
Repression of PGC-1a
Although hypoxia is associatedwithwidespread changes in gene
expression, including both induction and repression of numerous
genes, HIF-1a and HIF-2a function exclusively as transcriptional
activators of their direct target genes (Scho¨del et al., 2011). We
thus hypothesized that a transcriptional repressor must function
as an intermediate in PGC-1a suppression. Thebasic-helix-loop-
helix transcription factor Dec1 (Stra13/Bhlhe40) is a hypoxia-
inducible gene that acts as a transcriptional repressor (Sun and
Taneja, 2000). Interestingly, Dec1 has previously been reported
to suppress PPARg2 during adipocyte differentiation and PGC-
1a during myogenesis (Hsiao et al., 2009; Yun et al., 2002). We
thus hypothesized that Dec1 acts downstream of HIF stabiliza-
tion to functionally suppress PGC-1a in ccRCC.
In support of this hypothesis, Dec1 expression was inversely
correlated with PGC-1a in ccRCC and normal kidney samples
(Figure 5A). Dec1 protein levels were elevated in VHL-deficient
ccRCC cell lines, and suppression of Dec1 in these cells
increased PGC-1a mRNA and protein levels (Figures 5B–5D).
In VHL wild-type cells, DMOG treatment increased Dec1 protein
levels while decreasing PGC-1a protein levels (Figure 5E).
Consistent with an essential role for Dec1 as an effector of
HIF-mediated PGC-1a suppression, genetic inhibition of Dec1
abrogated suppression of PGC-1a expression in hypoxia (Fig-
ure 5F). Additionally, in VHL wild-type TK10 cells, inhibition of
Ppargc1a promoter activity by DMOG treatment requiredexpression of Dec1 (Figure 5G). Phylogenetic analysis of the
Ppargc1a promoter revealed two highly conserved putative
Dec1 binding sites, indicating the evolutionary importance of
Dec1-mediated regulation of PGC-1a (Figures S5D–S5F). To
examine whether Dec1 could suppress PGC-1a in the absence
of HIF-activation, we ectopically expressed Dec1 in TK10 cells
and found that Dec1 expression was sufficient to suppress
PGC-1a (Figure 5H). Together, these results indicate that Dec1
is necessary and sufficient for suppression of PGC-1a in ccRCC
and provide a mechanistic link between HIF, the predominant
oncogenic driver of ccRCC, and PGC-1a.
PGC-1a Expression Suppresses ccRCC Tumor Growth
Given our finding that ectopic PGC-1a expression stimulates
oxidative stress in ccRCC cells, we hypothesized that restored
expression of PGC-1a could suppress ccRCC growth. Support-
ing this hypothesis, PGC-1a expression inhibited growth of two
VHL-deficient ccRCC cell lines in vitro (Figures 6A and 6B).
Consistent with the anti-proliferative effects of PGC-1a expres-
sion in vitro, subcutaneous growth of 786-O tumors was signifi-
cantly impaired by expression of PGC-1a (Figures 6C and S6).
Furthermore, PGC-1a-transduced 786-O tumors were charac-
terized by an apparent reduction in the clear cell morphology
(Figure 6D). Consistent with our in vitro data indicating that
PGC-1a expression is sufficient to stimulate increased mito-
chondrial content, immunohistochemical (IHC) analysis of 786-
O tumors revealed increased expression of the mitochondrial
protein Tom20 in tumors expressing PGC-1a (Figures 6E).
Corroborating our in vitro data that PGC-1a expression induces
oxidative stress in ccRCC cells, PGC-1a-transduced tumors ex-
hibited elevated levels of 8oxoG and gH2AX (Figures 6F and 6G).
These results indicate that increased expression of PGC-1a in-
hibits ccRCC growth and highlight the potential of PGC-1a in-
duction as a therapeutic modality in the treatment of ccRCC.
To assess the impact of PGC-1a expression in clinical cases of
ccRCC, we next analyzed RNA sequencing data from over 500
patients with ccRCC from the Cancer Genome Atlas (TCGA) to
further explore the role of PGC-1a in ccRCC tumorigenesis.
These analyses revealed that low expression of PGC-1a was
significantly correlated with worse overall survival than patients
whose tumors expressed relatively high levels of PGC-1a
(Figure 6H). Consistent with these findings, patients harboring
tumors with low expression of PGC-1a were significantly more
likely to have advanced-stage tumors and metastatic disease
(Figure 6I and 6J). Together, these results indicate that low
expression of PGC-1a may be a prognostic factor in ccRCC.
DISCUSSION
Our data indicate that PGC-1a is suppressed in VHL-deficient
ccRCC through HIF-dependent induction of the transcriptional
repressor, Dec1. In VHL wild-type proximal tubule cells, PGC-1a
suppression disrupts mitochondrial respiration. Conversely,
rescued expression of PGC-1a in VHL-deficient ccRCC cell lines
restores mitochondrial function in an ERRa-dependent manner.
Importantly, the increases in mitochondrial respiration upon
expression of PGC-1a are associated with induction of oxidative
stress in ccRCC cell lines. In addition to stimulating oxidativeCell Reports 12, 116–127, July 7, 2015 ª2015 The Authors 121
Figure 4. Regulation of PGC-1a Expression by HIF-1a and HIF-2a
(A) Western blots of VHL-deficient RCC4 cells transduced with shCTRL, shHIF-1a, or shHIF-2a
(B) Western blots of VHL-deficient 786-O cells transduced with shCTRL or shHIF-2a.
(C) Western blots of RCC4 cells transduced with shCTRL or shARNT.
(D) PGC-1a mRNA levels in RCC4 and 786-O cells transduced with shCTRL or shARNT. *p < 0.05 by Student’s two-tailed t test.
(legend continued on next page)
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stress, PGC-1a expression also sensitizes VHL-deficient ccRCC
lines to cytotoxic therapies and inhibits in vitro and in vivo growth,
highlighting thepotential of targeting this pathway in the treatment
of ccRCC. In clinical ccRCC datasets, PGC-1a expression is
decreased compared to normal renal cortex, and low levels of
PGC-1a expression are associated with poor outcome, further
indicating that PGC-1a can suppress ccRCC tumorigenesis.
PGC-1a has been reported to have pro- or anti-tumorigenic
function in various tumors, but the reasons for this heteroge-
neous response remain unclear. One possibility is that PGC-1a
interacts with different tissue-specific transcription factors,
thus driving distinct genetic programs in different cancer types.
However, increased mitochondrial biogenesis appears to be a
ubiquitous response to PGC-1a expression regardless of the
cancer type or outcome of PGC-1a expression. Given this, we
postulate that the outcome of PGC-1a expression on tumor
growth is likely dictated at least in part by whether the ge-
netic landscape or tumor microenvironment are permissive to
increased mitochondrial activity. For example, LeBleu et al.
report increased PGC-1a in circulating tumor cells (CTCs) rela-
tive to the primary orthotopic tumor. One could reasonably
expect themetabolic demands of CTCs in the oxygen-rich circu-
latory system to be different from a hypoxic cancer cell. In the
case of ccRCC, the increased production of ROS upon expres-
sion of PGC-1a is inadequately detoxified, leading to oxidative
stress. Whether the antioxidant response dictates outcome to
enhanced mitochondrial biogenesis downstream of PGC-1a
activation will require further investigation.
PGC-1a expression is induced in a subset of melanomas
where its expression is regulated by MITF (Haq et al., 2013; Vaz-
quez et al., 2013). Interestingly, hypoxia negatively regulates
MITF expression through induction of Dec1, the same transcrip-
tional repressor implicated in our studies as a repressor of PGC-
1a (Feige et al., 2011). These results suggest that the tumor
microenvironment could play ameaningful role in dictating tumor
response to PGC-1a expression. Future studies will be needed
to fully understand themechanisms underlying these differences
in tumor response to PGC-1a and the clinical implications
thereof.
Here, we demonstrate that restored expression of PGC-1a in-
creases mitochondrial content, ROS production, and oxidative
damage, with the ultimate effect of impaired tumor growth
and enhanced therapeutic response. ccRCC tumors are typi-
cally refractory to cytotoxic chemotherapy and radiotherapy,
but the induction of PGC-1a may present an opportunity to
enhance efficacy and improve the treatment of ccRCC. Despite(E) Western blots of VHL wild-type HK2 and TK10 cells cultured in normoxia (21%
(F) PGC-1a mRNA levels in HK2 and TK10 cells cultured in normoxia (21% O2 [N
(G) PGC-1a mRNA levels in TK10 cells transduced with shCTRL, shHIF-1a, or sh
(0.5% O2 [Hx]) for 24 hr. *p < 0.0005; **p < 0.001; n.s., p > 0.06 by Student’s two
(H) Western blots of TK10 cells transduced with shCTRL, shHIF-1a, or shHIF-2a
(I) PGC-1amRNA levels in TK10 cells transduced with shCTRL, shHIF-1a, or shHI
for 24 hr. *p < 0.001 by Student’s two-tailed t test.
(J)Ppargc1a promoter reporter activity (firefly luciferase/CMV-Renilla luciferase ac
2a and cultured in vehicle (Veh) or 1 mM DMOG for 18 hr. Two-tailed Student’s t
versus shHIF-1a DMOG: p < 0.005; n.s., shCTRL DMOG versus shHIF-2a DMOG
All bar graphs are plotted as mean ± SD. See also Figure S5.the apparent difficulties associated with targeting transcription
factors, several groups have conducted high-throughput
screens that have identified both transcriptional and post-trans-
lational activators of PGC-1a (Arany et al., 2008; Lee et al.,
2014). In the future, it will be important to determine whether
the pharmacological activation of PGC-1a, either through
increasing PGC-1a expression or activating the existing pool
of endogenous PGC-1a, is a viable therapeutic modality for
the treatment of ccRCC.
EXPERIMENTAL PROCEDURES
Cell Culture
Cells were cultured in DMEM + 10% complete or charcoal-stripped fetal
bovine serum (FBS) where indicated. Human PGC-1a cDNA was ectopically
expressed by retroviral transduction using the pLPC vector. All shRNA
constructs other than shHIF-1a (pSIREN) were in pLKO.1 vector and were
purchased from Open Biosystems. Cell viability was assessed by XTT assay
as described previously (Turcotte et al., 2008). For clonogenic assays, cells
were pre-treated for 48 hr with the indicated dose of doxorubicin or irradi-
ated with the indicated dose of ionizing radiation, cultured for 10 days, and
stained with crystal violet to visualize colonies. Clonogenic survival was
determined by dividing the number of surviving colonies by the number of
cells plated. For siRNA experiments, ON-TARGETplus siRNA SMARTpools
containing four siRNAs were purchased from Dharmacon. siRNAs were
transfected into cells using Dharmafect1 transfection reagent (Dharmacon),
and cells were collected for gene expression analysis or extracellular flux
analysis 48 hr post-transfection. All cell lines used in these studies have
been previously described elsewhere (Bear et al., 1987; Maxwell et al.,
1999; Ryan et al., 1994).
Extracellular Flux Analysis
OCR/ECAR measurements were performed using XF96 extracellular flux
analyzer (Seahorse Biosciences). Experiments were conducted in DMEM
with 5% FBS, 25 mM glucose, 2 mM glutamine, and 1 mM pyruvate, but
without NaHCO3. Inhibitors were injected to final concentrations of 2.5 mg/ml
oligomycin, 5 mM FCCP, 2.5 mM antimycin A, 1 mM rotenone, and 100 mM eto-
moxir. All chemicals were purchased from Sigma-Aldrich.
GC-MS Metabolomics
Cell pellets were extracted with 0.45 ml water/methanol (1:1 volume, contain-
ing 20 mML-norvaline) and 0.225ml chloroform containing 4 mg/ml heptadeca-
noic acid as described in detail before (Ratnikov et al., 2015; Scott et al., 2011).
Polar metabolites extracted into the water/methanol phase were derivatized
and analyzed by GC-MS.
Luciferase Assays
A 1.8 kb region of the proximal Ppargc1a promoter was cloned from HK2
cells into the pGL3-basic reporter plasmid (Promega). TK10 cells were
transiently transfected with this construct along with cytomegalovirus
(CMV)-Renilla reporter to monitor transfection efficiency. Firefly and RenillaO2 [Nx]) or hypoxia (0.5% O2 [Hx]) for the indicated time (hr).
x]) or hypoxia (0.5% O2 [Hx]) for 24 hr. *p < 0.01 by Student’s two-tailed t test.
HIF-2a shRNA constructs and cultured in normoxia (21% O2 [Nx]) or hypoxia
-tailed t test.
and cultured in normoxia (21% O2, Nx) or hypoxia (0.5% O2, Hx) for 24 hr.
F-2a shRNA constructs and treated with 1mMDMOG or vehicle control (CTRL)
tivity [RLU]) in TK10 cells transducedwith control, shCTRL, shHIF-1a, or shHIF-
test results: *shCTRL Veh versus shCTRL DMOG: p < 0.05; **shCTRL DMOG
: p = 0.23.
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Figure 5. Dec1 Is Necessary and Sufficient for Transcriptional Suppression of PGC-1a
(A) mRNA expression of PGC-1a andDec1 in renal cortex and ccRCC tumors. GEO accession number GEO:GSE6344. Pearson correlation co-efficient r=0.55,
two-tailed t test p = 0.0018.
(B) Western blots of VHL-deficient (VHL) or wild-type (+VHL) RCC4 and 786-O cells.
(C) Western blots of RCC4 and 786-O cells transduced with shCTRL or shDec1.
(D) PGC-1a mRNA levels in RCC4 and 786-O cells transduced with shCTRL or shDec1. *p = 0.01 by Student’s two-tailed t test shDec1 versus shCTRL.
(E) Western blots of VHL wild-type HK2 and TK10 cells treated with vehicle or 0.1, 0.5, or 1 mM DMOG for 24 hr.
(F) PGC-1amRNA levels in TK10 and HK2 cells transduced with shCTRL or shDec1 and cultured in normoxia (Nx) or hypoxia (Hx) for 24 hr. *p = 0.017; **p < 0.05;
***p% 0.0001.; n.s. p > 0.05 by Student’s two-tailed t test.
(G) Ppargc1a promoter reporter activity (firefly luciferase/CMV-Renilla luciferase activity [RLU]) in vehicle- (Veh) and DMOG-treated (1mM) TK10 cells transduced
with shCTRL or shDec1. *p < 0.02; n.s., p > 0.05 by Student’s two-tailed t test.
(H) Western blots of TK10 cells ectopically expressing Dec1.
All bar graphs are plotted as mean ± SD. See also Figure S5.luciferase levels were quantified with Bright-Glo and Renilla luciferase assays
(Promega).
Microarray and RNA-Sequencing Analysis
GEO:GSE6344 and GEO:GSE15641 were selected for analysis from the GEO
database due to the representation of both normal renal cortex and ccRCC
specimens within each dataset (Gumz et al., 2007; Jones et al., 2005; Tun
et al., 2010). For GEO:GSE15641, data from non-ccRCC subtypes of kidney
cancer were excluded from our analysis. Datasets were analyzed using the
GSEA module in the GenePattern software suite (Reich et al., 2006; Subrama-124 Cell Reports 12, 116–127, July 7, 2015 ª2015 The Authorsnian et al., 2005). Microarrays comparing expression changes in VHL-deficient
and wild-type RCC4 cells and after culture of RCC4+VHL cells in hypoxia have
been previously described (Krieg et al., 2010). Differentially expressed genes
above or below a fold change threshold (>1.5-fold or <1.5-fold) in both data-
sets were analyzed using the DAVID functional annotation tool (Huang et al.,
2009a, 2009b).
Ppargc1a expression levels were extracted from level 3 RNA-sequencing
data from the KIRC TCGA dataset using the ‘‘normalized_count’’ parameter
(https://tcga-data.nci.nih.gov/tcga/) and matched by TCGA barcode with cor-
responding clinical information including time to death or last follow-up,
Figure 6. PGC-1a Suppresses ccRCC Growth
(A) In vitro growth curves of CTRL or PGC-1a-transduced RCC4 cells.
(B) In vitro growth curves of CTRL or PGC-1a-transduced 786-O cells. *p < 0.05 by Student’s two-tailed t test.
(C) Subcutaneous tumor volume of CTRL or PGC-1a-transduced 786-O cells. Mixed-effects model p < 0.0001 between CTRL and PGC-1a.
(D) H&E-stained CTRL or PGC-1a-transduced 786-O subcutaneous tumors. Arrows denote cells with evident clear cell morphology. Scale bar, 100 mm.
(E) Tom20 immunohistochemical (IHC) staining of CTRL or PGC-1a-transduced 786-O subcutaneous tumors. Arrows denote cells with strong perinuclear Tom20
staining. Scale bar, 100 mm.
(F) 8oxoG IHC staining of CTRL or PGC-1a-transduced 786-O subcutaneous tumors. Arrows denote nuclei with strongly positive 8oxoG staining. Scale
bar, 25 mm.
(G) gH2Ax IF staining of CTRL or PGC-1a-transduced 786-O subcutaneous tumors. Nuclei were counterstained with DAPI. Scale bar, 25 mm.
(H) Kaplan-Meier Curve for ccRCC patients segregated by low (bottom quartile) or high expression of PGC-1a. Log-rank test p < 0.0001.
(I) Percentage of patients with AJCC stage I–IV disease, segregated by PGC-1a expression as in (H).
(J) Percentage of patients with detectable metastases. Patients are segregated by PGC-1a expression as in (H).
All bar graphs are presented as mean ± SD. See also Figure S6.American Joint Committee on Cancer tumor staging, and the presence or
absence of metastatic disease. To segregate patients according to high or
low expression of PGC-1a, themedian expression from all patients in the data-
set was calculated and patients were segregated into the PGC-1a-low group if
PGC-1a expression in the tumor was in the bottom quartile of expression. The
remaining patients were included in the PGC-1a-high group.
Microscopy and Immunohistochemistry
For fluorescent labeling of mitochondria, live cells were incubated with 100 nM
CMXROS (Molecular Probes) in buffer containing 100 mM KCl to depolarize
the mitochondrial membrane for 30 min at 37C. Antibodies used for IHC
and immunofluorescence experiments were 8-hydroxyguanosine (Abcam),gH2AX (Millipore), and Tom20 (Santa Cruz). For IHC experiments, primary anti-
body labeling was detected after incubation with the appropriate secondary
antibody by incubation with 3, 30-diaminobenzidine (DAB; Vector Labs). For
IF experiments, nuclei were counterstained for 5 min with DAPI. For IHC stain-
ing experiments, slides were counterstained with hematoxylin.
Quantitative Real-Time PCR
mRNA was extracted from cells using Trizol (Invitrogen) and reverse tran-
scribed using Superscript II reverse transcriptase (Invitrogen). Relative
mRNA levels were calculated using the standard curve methodology. For
mtDNA quantification, total DNA was isolated from cultured cells using
phenol/chloroform/isoamyl alcohol (Invitrogen). Primers were designed toCell Reports 12, 116–127, July 7, 2015 ª2015 The Authors 125
amplify the 16S rRNA gene from the mtDNA genome and were normalized to
the nuclear gene b2-microglobulin. A complete list of primer sets can be found
in Table S1.
ROS Measurements
Live cells were stained with either DCF-DA or MitoSOX stains according to
manufacturer-recommended protocol. Briefly, cells were incubated with
10 mM DCF-DA (Molecular Probes) or 5 mM MitoSOX Red (Life Technologies)
for 30 min at 37C. After PBS wash, cells were analyzed by flow cytometry
using an LSRII flow cytometer (Becton Dickenson).
Western Blotting
Western blot images were acquired using the ChemiDoc CCD imaging system
(Bio-Rad). The following antibodies were used for western blotting: ARNT
(Novus), b-actin (Sigma-Aldrich), Dec1 (Novus), HIF-1a (BD), HIF-2a (Novus),
HSP70 (Sigma-Aldrich), PGC-1a (Sigma-Aldrich and Santa Cruz), and Tfam
(Sigma-Aldrich). Densitometry analysis was performed using ImageJ software,
and relative values were calculated by normalizing to the control group from
each experiment (Schneider et al., 2012).
Xenograft Tumor Growth
5 3 106 control (CTRL) or PGC-1a-transduced 786-O cells were injected into
the flanks of non-obese diabetic/severe combined immunodeficiency mice
(n = 5 for control group, n = 8 for PGC-1a group). Tumor size was measured
weekly, and volume was calculated according to the following formula: vol-
ume = (width2 3 length)O 2.
Because the tumor volumes of the mice in both treatment groups (CTRL and
PGC-1a) followed a log-normal distribution, the data were log transformed to
render the data normally distributed and to analyze the data in a mixed-effects
model. The data were analyzed in a mixed-effects model to accommodate the
repeated measure of tumor volume over time. The effect of treatment was
included as a fixed effect in the model, and day was included as a random
effect. The variance-covariance matrix was assumed to have a compound
symmetry structure. In the final model, the treatment effect (CTRL versus
PGC-1a) was significant (treatment p < 0.0001).
All animal experiments were conducted in accordance with standard institu-
tional animal care and use committee protocols.
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